Hinova Pharmaceuticals Inc. (SHA:688302)
China
· Delayed Price · Currency is CNY 50.86
+1.66 (3.37%)
At close: Jul 4, 2025, 2:57 PM CST
Hinova Pharmaceuticals Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2018 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2018 - 2019 |
Other Revenue | 0.37 | 0.37 | - | 1.65 | - | - | Upgrade
|
| 0.37 | 0.37 | - | 1.65 | - | - | Upgrade
| |
Cost of Revenue | 0.34 | 0.34 | - | 0.77 | - | - | Upgrade
|
Gross Profit | 0.03 | 0.03 | - | 0.88 | - | - | Upgrade
|
Selling, General & Admin | 54.45 | 53.49 | 88 | 97.04 | 80.28 | 61.9 | Upgrade
|
Research & Development | 156.82 | 174.03 | 248.27 | 251.37 | 264.93 | 428.93 | Upgrade
|
Other Operating Expenses | 1.61 | 0.41 | 0.42 | 0.35 | 0.06 | 0.47 | Upgrade
|
Operating Expenses | 213.21 | 227.94 | 336.69 | 348.75 | 345.27 | 491.3 | Upgrade
|
Operating Income | -213.18 | -227.91 | -336.69 | -347.87 | -345.27 | -491.3 | Upgrade
|
Interest Expense | -0.59 | -0.53 | -1.49 | -3.92 | -2.56 | -0.36 | Upgrade
|
Interest & Investment Income | 17.55 | 19.16 | 28.62 | 22.5 | 26.97 | 7.41 | Upgrade
|
Currency Exchange Gain (Loss) | 1.35 | 1.35 | 1.4 | 7.56 | -2.1 | -5.23 | Upgrade
|
Other Non Operating Income (Expenses) | -0.52 | -0.43 | -0.39 | -0.17 | -0.14 | -10.06 | Upgrade
|
EBT Excluding Unusual Items | -195.39 | -208.36 | -308.54 | -321.9 | -323.11 | -499.54 | Upgrade
|
Gain (Loss) on Sale of Investments | 4.21 | 3.96 | 8.35 | 10.27 | -1.5 | - | Upgrade
|
Gain (Loss) on Sale of Assets | 0 | 0 | 0.01 | -0 | -0 | - | Upgrade
|
Asset Writedown | - | - | - | - | - | -0.02 | Upgrade
|
Other Unusual Items | 6.81 | 4.91 | 6.04 | 10.12 | 18.44 | 9.71 | Upgrade
|
Pretax Income | -184.37 | -199.48 | -294.14 | -301.51 | -306.18 | -489.85 | Upgrade
|
Income Tax Expense | 0.01 | 0.01 | 0.02 | - | - | - | Upgrade
|
Earnings From Continuing Operations | -184.38 | -199.5 | -294.16 | -301.51 | -306.18 | -489.85 | Upgrade
|
Minority Interest in Earnings | - | - | - | - | - | 0 | Upgrade
|
Net Income | -184.38 | -199.5 | -294.16 | -301.51 | -306.18 | -489.85 | Upgrade
|
Net Income to Common | -184.38 | -199.5 | -294.16 | -301.51 | -306.18 | -489.85 | Upgrade
|
Shares Outstanding (Basic) | 100 | 99 | 99 | 91 | 74 | 70 | Upgrade
|
Shares Outstanding (Diluted) | 100 | 99 | 99 | 91 | 74 | 70 | Upgrade
|
Shares Change (YoY) | 0.91% | 0.21% | 9.06% | 22.21% | 5.74% | - | Upgrade
|
EPS (Basic) | -1.85 | -2.01 | -2.97 | -3.32 | -4.12 | -6.97 | Upgrade
|
EPS (Diluted) | -1.85 | -2.01 | -2.97 | -3.32 | -4.12 | -6.97 | Upgrade
|
Free Cash Flow | -251 | -276.63 | -354.68 | -384.13 | -247.6 | -246.16 | Upgrade
|
Free Cash Flow Per Share | -2.52 | -2.79 | -3.58 | -4.23 | -3.33 | -3.50 | Upgrade
|
Gross Margin | 8.43% | 8.43% | - | 53.57% | - | - | Upgrade
|
Operating Margin | -58112.66% | -62127.45% | - | -21072.49% | - | - | Upgrade
|
Profit Margin | -50262.97% | -54382.81% | - | -18264.53% | - | - | Upgrade
|
Free Cash Flow Margin | -68422.12% | -75410.46% | - | -23269.07% | - | - | Upgrade
|
EBITDA | -211.16 | -225.83 | -334.4 | -345.96 | -342.22 | -490.1 | Upgrade
|
D&A For EBITDA | 2.02 | 2.07 | 2.28 | 1.91 | 3.05 | 1.2 | Upgrade
|
EBIT | -213.18 | -227.91 | -336.69 | -347.87 | -345.27 | -491.3 | Upgrade
|
Revenue as Reported | 0.37 | 0.37 | - | 1.65 | - | - | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.